21. Rubraca

breast cancer

Active ingredient: rucaparib
Disease: ovarian cancer
Peak sales estimate: $750 million to $1 billion
Approved: Dec. 19
Company: Clovis Oncology

The Scoop: With an accelerated approval ahead of its February 2017 PDUFA date, Clovis Oncology’s Rubraca is set to launch and challenge AstraZeneca’s Lynparza. A PARP inhibitor, Rubraca won FDA approval as a third-line ovarian cancer treatment for patients who have the BRCA gene mutation. Clovis priced the drug at $6,870 for a 15-day supply and already has its 85-person sales force calling on docs, execs told investors during a conference call following the approval. About 15% to 20% of ovarian cancer patients have the BRCA gene mutation, according to the FDA; the agency approved a companion diagnostic to test for the mutation on the same day. Aside from AZ, AbbVie, Pfizer and Tesaro each have potential PARP challengers in their respective pipelines.

21. Rubraca

Suggested Articles

Medimmune’s Ronald Herbst, Ph.D., has followed a series of other AstraZeneca and its biologics arm staffers out the door.

The takeover will give Alexion two clinical-phase medicines in development in complement alternative pathway-mediated rare diseases.

Last year, Eli Lilly spent $1.6 billion to get its hands on Armo Biosciences and its lead asset, pegilodecakin. Today, that drug flopped.